Comparing Acetazolamide and Metolazone Added to Standard Treatment for Adults with Acute Decompensated Heart Failure

What this Trial Is About

Researchers are evaluating the effectiveness and safety of acetazolamide versus metolazone when added to standard treatment in patients with acute decompensated heart failure ADHF. This condition is serious and often treated with loop diuretics to reduce excess fluid. The study aims to determine which adjunct therapy better improves fluid removal, shortens hospital stays, and reduces complications like kidney problems or electrolyte imbalances. The trial is focused on patients with ADHF, including those with preserved or reduced heart function. Participants will be randomly assigned to receive either acetazolamide at 500 mg daily or metolazone at 5 mg daily, both alongside standard intravenous loop diuretics furosemide 80 mg per day. These treatments are given orally for three days to assess their role in enhancing fluid removal. The trial compares these two adjunct therapies to see which is more effective and safe in managing fluid overload in ADHF. During the study, patients will be closely monitored for successful fluid removal after 72 hours of treatment, along with hospital stay duration and in-hospital mortality. Researchers will also watch kidney function, electrolyte levels, and any side effects. The study takes place at a hospital setting and involves routine clinical assessments, imaging to confirm fluid overload, and blood tests to measure heart failure markers. Total participation duration covers the initial treatment and hospital stay.

Comparative Efficacy and Safety of Acetazolamide Versus Metolazone as an Adjunct to Standard Therapy in Patients With Acute Decompensated Heart Failure